MENU
Showcases Stock ranks Forex

Sorrento Therpt (SRNE)
0.3073  0 (0%) 02-22 16:00
Open: 0.4247 Pre. Close: 0.3073
High: 0.4735 Low: 0.26
Volume: 173,468,227 Market Cap: 168(M)
Stock Technical Analysis
Overall:     
Target: Six months: 0.42
One year: 0.47
Support: Support1: 0.29
Support2: 0.24
Resistance: Resistance1: 0.36
Resistance2: 0.40
Pivot: 0.34
Moving Averages: MA(5): 0.34
MA(20): 0.34
MA(100): 0.70
MA(250): 1.41
MACD: MACD(12,26): -0.02
Signal(12,26,9): -0.02
%K %D: %K(14,3): 38.53
%D(3): 39.75
RSI: RSI(14): 44.42
52-Week: High: 3.09
Low: 0.161
Change(%): -78.7
Average Vol(K): 3-Month: 31170
10-Days: 1861
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.35 - 0.352 0.352 - 0.353
Low: 0.326 - 0.328 0.328 - 0.329
Close: 0.337 - 0.34 0.34 - 0.342
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ SRNE ] has closed above bottom band by 36.4%. Bollinger Bands are 86.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Stock chart
Stock News
Wed, 20 Mar 2024
Sorrento Therapeutics (NASDAQ:SRNE) Share Price Crosses Below 200 Day Moving Average of $0.08 - Defense World

Wed, 20 Mar 2024
Sorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated by Analysts at StockNews.com - Defense World

Tue, 12 Mar 2024
Sorrento Therapeutics (NASDAQ:SRNE) Now Covered by Analysts at StockNews.com - Defense World

Tue, 27 Feb 2024
Sorrento COVIDTRAP™(STI-4398) Demonstrates in Preclinical Studies its Ability to Completely Inhibit SARS-CoV-2 ... - Investors

Wed, 22 Feb 2023
Bankrupt Sorrento Therapeutics Secures Court Approval for $75M Financing - Yahoo Finance

Thu, 16 Feb 2023
Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions - PR Newswire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M)
% Held by Insiders
% Held by Institutions
Shares Short (K)
Shares Short Prior Month (K)
Stock Financials
EPS
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) -0.305
Sales Per Share 0.110
EBITDA (p.s.) -0.713
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales 3.06
Price to Cash Flow
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android